Quick Takeaways
- Sofinnova Venture Partners X, L.P. filed SCHEDULE 13D/A for Vera Therapeutics, Inc. Class A Common Stock, $0.001 par value (VERA).
- Disclosed ownership: 4%.
- Date of event: 10 Dec 2025.
Quoteable Key Fact
"Sofinnova Venture Partners X, L.P. disclosed 4% ownership in Vera Therapeutics, Inc. Class A Common Stock, $0.001 par value (VERA) on 10 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sofinnova Venture Partners X, L.P. ("SVP X") | 3.9% | 2,793,987 | 2,793,987 | 0 | /s/ Nathalie Auber | Nathalie Auber / Attorney-in-Fact | 0001680200 |
| Sofinnova Management X, L.P. ("SM X LP") | 3.9% | 2,793,987 | 2,793,987 | 0 | /s/ Nathalie Auber | Nathalie Auber / Attorney-in-Fact | |
| Sofinnova Management X-A, L.L.C. ("SM X LLC") | 3.9% | 2,793,987 | 2,793,987 | 0 | /s/ Nathalie Auber | Nathalie Auber / Attorney-in-Fact | |
| Dr. James I. Healy ("Healy") | 3.9% | 2,793,987 | 0 | 2,793,987 | /s/ Nathalie Auber | Nathalie Auber / Attorney-in-Fact | |
| Dr. Maha Katabi ("Katabi") | 4% | 2,847,837 | 53,850 | 2,793,987 | /s/ Nathalie Auber | Nathalie Auber / Attorney-in-Fact |